New Treatment For Long-term Insomnia NICE Recommends The Treatment For Better Sleep! (1)

Anyone who has tossed and turned through the night, glaring at the clock, knows the struggle of insomnia. For those dealing with this night after night, a breakthrough by The National Institute for Health and Care Excellence (NICE) brings hope. They’ve highlighted daridorexant (QUVIVIQ, Idorsia) as a promising new treatment for chronic insomnia.

The Silent Struggle with Insomnia

Insomnia is the most common sleep disorder in the United States. It affects about one-third of the general population in the U.S. It doesn’t stop at stealing sleep—it affects one’s health, daily activities, and overall sense of well-being. It’s more than just sleepless nights. It’s also about navigating through life in a constant state of exhaustion and frustration. That can lead to decreased productivity and increased errors and accidents at work.

How Daridorexant Brings Hope

In this scenario, the emergence of daridorexant is like a ray of sunlight in the seemingly never-ending darkness. It’s potentially a new ally in the fight against the persistent struggle with sleep. It served as a second-line treatment for long-term insomnia as per NICE’s initial guidance.

What Makes Daridorexant Special?

Daridorexant operates uniquely—it zones in on the orexin system. It is a crucial player in our sleep and wake cycles. This system, when overactive, can keep people awake, causing relentless wakefulness, a characteristic of insomnia. Daridorexant blocks the activation of orexin receptors and calms this overactivity. It enables individuals to escape the loop of wakefulness and embrace the power of sleep.

The Current State of Insomnia Treatment

At present, dealing with insomnia usually begins with sleep advice and cognitive behavioral therapy for insomnia (CBTi). However, not everyone has access to CBTi. Some don’t even know it exists. That leaves them grappling in the dark for solutions.

The Journey and Potential of Daridorexant

Taken orally before bedtime, daridorexant has shown in trials its capability to reduce insomnia symptoms over 12 months. This is without leading to dependency or causing rebound insomnia after stopping. But it’s essential to note that questions still surround its long-term benefits and cost-effectiveness beyond a year.

Recommendations and Cautions from NICE

NICE proposes using daridorexant only after other initial treatments like CBTi have failed or where CBTi is not an option. It’s expected to benefit over 20,000 individuals in England in the coming year. However, NICE also stresses the importance of short treatment duration. It also suggests regular assessments from the beginning of the medication.

Hope for Insomnia Sufferers

For many, this advancement is more than scientific progress—it’s a lifeline. While various treatments are available, they might not be suitable or effective for everyone. Particularly for long-term use. The introduction of daridorexant is a significant step forward. It is providing a new avenue for those seeking respite from the clutches of chronic insomnia.

Vigilance in Treatment

Daridorexant is new and therefore strict monitoring is needed. Monitoring helps any damaging events to be promptly reported, ensuring the well-being of those counting on this treatment. The medical community and those affected by chronic insomnia are eagerly awaiting the final guidance from NICE. It is due on 18 October 2023.


The endorsement of daridorexant by NICE marks a pivotal moment for those silently suffering from chronic insomnia. It’s not merely a scientific breakthrough. It’s a sign of hope for life, a chance for peaceful nights. It reminds us that the pursuit of alleviating human suffering through science is relentless. In the world of sleepless nights and weary days, daridorexant stands as a beacon of renewed hope.

Also read,

Similar Posts